tradingkey.logo

Novartis is seeking to have key products for U.S. manufactured there, CEO says

ReutersApr 29, 2025 6:16 AM

- The CEO of Novartis NOVN.S said on Tuesday that the Swiss drugmaker is investing in the United States to no longer rely on dedicated production capacity in Europe and other regions that would serve the U.S., its biggest market.
"We now want to ensure that 100% of the demand of our key products in the U.S. is produced in the U.S.," CEO Vas Narasimhan said, declining to provide details on volumes.

Novartis said this month it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it grapples with renewed threats of drug import duties from the Trump administration.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI